Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jan;55(1):122-123.
doi: 10.1111/apt.16696.

Editorial: the role for PIVKA-II measurement after HCV elimination by direct-acting anti-virals in terms of prediction of hepatocellular carcinoma

Eiichi Ogawa  1
Affiliations
Editorial

Editorial: the role for PIVKA-II measurement after HCV elimination by direct-acting anti-virals in terms of prediction of hepatocellular carcinoma

Eiichi Ogawa. Aliment Pharmacol Ther. 2022 Jan.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301-1314.
    1. Ogawa E, Toyoda H, Iio E, et al. Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: a practice implication. Clin Infect Dis. 2020;71:2840-2848.
    1. Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology. 2020;71:44-55.
    1. Calvaruso V, Craxì A. Hepatic benefits of HCV cure. J Hepatol. 2020;73:1548-1556.
    1. Degasperi E, Perbellini R, D’Ambrosio R, et al. Prothrombin induced by vitamin K absence or antagonist- II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C- related cirrhosis treated with direct- acting antiviral agents. Aliment Pharmacol Ther. 2021.doi: 10.1111/apt.16685.

LinkOut - more resources